Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01289080 · ClinicalTrials.gov registry record · Phase 1
Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects
A Phase 1 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01289080 is a Phase 1 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 19 participants.
The verdict
NCT01289080, a Phase 1 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This trial is an open-label, multi-center, parallel-arm, single-dose trial in 2 groups: 1 group of subjects with normal renal function and 1 group of severely renally impaired subjects.
Interventions
- DRUG OPC-34712
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01289080
The ClinicalTrials.gov registry entry for NCT01289080 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OPC-34712 is the first listed.
NCT01289080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01289080 about?
NCT01289080 is a clinical study titled "Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects". This trial is an open-label, multi-center, parallel-arm, single-dose trial in 2 groups: 1 group of subjects with normal renal function and 1 group of severely renally impaired subjects.
What is the current status of trial NCT01289080?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2011-01. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01289080?
The interventions under investigation include: OPC-34712 (DRUG).
Who is sponsoring clinical trial NCT01289080?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.